Research programme: antiviral therapeutics - Kovina Therapeutics
Alternative Names: HPV related Cancer Therapeutics - Kovina TherapeuticsLatest Information Update: 16 Jul 2024
At a glance
- Originator Indiana University
- Developer Kovina Therapeutics
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Human papillomavirus E6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Human papillomavirus infections
Most Recent Events
- 16 Jul 2024 Pharmacodynamics data from preclinical studies in Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 01 Nov 2022 Kovina Therapeutics receives SBIR one-year phase I grant from National Institute of Dental and Craniofacial Research for antiviral therapeutics development in Oropharyngeal cancer caused by HPV infections
- 05 Jul 2022 Kovina Therapeutics receives STTR grant from National Cancer Institute to support development of therapeutic treatments for HPV related cancers